Tag:

Trikafta

The editor takes stock of a significant year for the FK community, marked by access to Trikafta and an issue rich in testimonies, expertise and scientific advances.

The addition of Trikafta to the RAMQ in September 2021 marks a major advance for cystic fibrosis in Quebec by making available a treatment that acts on the cause of the disease for eligible people.

Sophie Vaillancourt testifies to the pain and feeling of injustice experienced by people with class 1 mutations, for whom CFTR modulators are not an option, while calling for equitable access to treatments for those who can benefit from them.

Research has profoundly improved the prognosis of cystic fibrosis thanks to CFTR modulators, with new hope for all patients despite challenges in accessing treatments.

This study shows that delayed access to Trikafta would lead to more serious lung diseases, more exacerbations, more deaths, and significantly lower life expectancy in people with cystic fibrosis compared to early access.